As we refined the sophistication of the approach and the mutation classification, the algorithms and the sequencing, it has become clear that this was a big challenge that would require coordinated investment and organisation, we have to collect five to ten thousand tumour samples and normal blood, we have to quality-control the DNA sequencing and do the data management and statistics -- it's a combination of large-scale epidemiology and large-scale genomics that haven't been married together in this way before.